Search hospitals > Indiana > Indianapolis

Dawes Fretzin Clinical Research Group, LLC

Claim this profile
Indianapolis, Indiana 46250
Global Leader in Plaque Psoriasis
Global Leader in Atopic Dermatitis
Conducts research for Vasculopathic Skin Disease
Conducts research for Eczema
Conducts research for Psoriasis
141 reported clinical trials
4 medical researchers
Photo of Dawes Fretzin Clinical Research Group, LLC in IndianapolisPhoto of Dawes Fretzin Clinical Research Group, LLC in IndianapolisPhoto of Dawes Fretzin Clinical Research Group, LLC in Indianapolis

Summary

Dawes Fretzin Clinical Research Group, LLC is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Plaque Psoriasis, Atopic Dermatitis, Vasculopathic Skin Disease, Eczema, Psoriasis and other specialties. Dawes Fretzin Clinical Research Group, LLC is involved with conducting 141 clinical trials across 92 conditions. There are 4 research doctors associated with this hospital, such as Scott Fretzin, Kenneth W Dawes, Scott Alfred Fretzin, and John S Barbieri, MD, MBA.

Top PIs

Clinical Trials running at Dawes Fretzin Clinical Research Group, LLC

Atopic Dermatitis
Chronic Urticaria
Eczema
Plaque Psoriasis
Vasculopathic Skin Disease
Hidradenitis Suppurativa
Psoriasis
Cutaneous Lupus Erythematosus
Lupus
Obesity
Image of trial facility.

Rocatinlimab

for Atopic Dermatitis/Eczema

This trial is testing rocatinlimab to see if it is safe and can be tolerated by people with moderate-to-severe eczema. The medication works by calming the immune system to reduce skin inflammation and irritation.
Recruiting1 award Phase 31 criteria
Image of trial facility.

Amlitelimab

for Atopic Dermatitis (SHORE)

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe atopic dermatitis (AD) with a history of inadequate response of topical treatment, on background topical corticosteroid (TCS) and/or topical calcineurin inhibitor (TCI). The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate to severe AD aged 12 years and older on background TCS and/or TCI. Study details include: At the end of the treatment period, participants will have an option to enter a separate study: the blinded extension study EFC17600 (ESTUARY). For participants not entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 44 weeks including a 2 to 4-week screening, a 24-week randomized double-blind period, and a 16-week safety follow-up. For participants entering the blinded extension Study EFC17600 (ESTUARY), the study duration will be up to 28 weeks including a 2 to 4-week screening and a 24-week randomized double-blind period. The total treatment duration will be up to 24 weeks. The total number of visits will be up to 10 visits (or 9 visits for those entering the blinded extension study EFC17600 (ESTUARY).
Recruiting1 award Phase 33 criteria
Image of trial facility.

PF-07275315 + PF-07264660

for Eczema

This trial is testing two new medicines, PF-07275315 and PF-07264660, given as shots to adults with moderate to severe atopic dermatitis that hasn't improved with other treatments. The goal is to see if these medicines are safe and effective in reducing the symptoms of this itchy red rash.
Recruiting0 awards Phase 2

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Dawes Fretzin Clinical Research Group, LLC?
Dawes Fretzin Clinical Research Group, LLC is a medical facility located in Indianapolis, Indiana. This center is recognized for care of Plaque Psoriasis, Atopic Dermatitis, Vasculopathic Skin Disease, Eczema, Psoriasis and other specialties. Dawes Fretzin Clinical Research Group, LLC is involved with conducting 141 clinical trials across 92 conditions. There are 4 research doctors associated with this hospital, such as Scott Fretzin, Kenneth W Dawes, Scott Alfred Fretzin, and John S Barbieri, MD, MBA.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security